Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma.

NCT06697301 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

740

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Melanoma

Interventions

DRUG: EIK1001
DRUG: Pembrolizumab (KEYTRUDA® )

Sponsor

Eikon Therapeutics

Collaborators

[object Object]